Pub Date : 2021-01-29eCollection Date: 2021-01-01DOI: 10.1155/2021/6690715
Meenakshi Devi Parre, B Sujatha
The global requirement of patient rehabilitation has surged with time due to the growing number of accidents, injuries, age-related issues, and other aspects. Parallelly, the cost of treatment and patient care also increased in a manifold. Moreover, constant monitoring and support for the patients having physical disabilities have become an ongoing challenge to the medical system. Robotics-based neurorehabilitation has reduced the human error while assisting such patients, precisely interpreting the signals, and communicating to the patient. Gradual precise application and improvement of the technology with time yielded a novel direction for patient care and support. The interdisciplinary contribution of many advanced technical branches allowed us to develop robotics-based assistance with high precision for the upper limb and the lower limb impairments. The present review summarizes the generation and background of robotic implementation for patient support, progress, present status, and future requirements.
{"title":"Novel Human-Centered Robotics: Towards an Automated Process for Neurorehabilitation.","authors":"Meenakshi Devi Parre, B Sujatha","doi":"10.1155/2021/6690715","DOIUrl":"https://doi.org/10.1155/2021/6690715","url":null,"abstract":"<p><p>The global requirement of patient rehabilitation has surged with time due to the growing number of accidents, injuries, age-related issues, and other aspects. Parallelly, the cost of treatment and patient care also increased in a manifold. Moreover, constant monitoring and support for the patients having physical disabilities have become an ongoing challenge to the medical system. Robotics-based neurorehabilitation has reduced the human error while assisting such patients, precisely interpreting the signals, and communicating to the patient. Gradual precise application and improvement of the technology with time yielded a novel direction for patient care and support. The interdisciplinary contribution of many advanced technical branches allowed us to develop robotics-based assistance with high precision for the upper limb and the lower limb impairments. The present review summarizes the generation and background of robotic implementation for patient support, progress, present status, and future requirements.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2021 ","pages":"6690715"},"PeriodicalIF":1.5,"publicationDate":"2021-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25351260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-28eCollection Date: 2021-01-01DOI: 10.1155/2021/6681554
Nicole Peters, Vanina Dal Bello-Haas, Tara Packham, Ava Mehdipour, Ayse Kuspinar
Objective: The aim of this review was to synthesize the psychometric properties of generic preference-based measures (PBMs) of health-related quality of life (HRQL) in Amyotrophic Lateral Sclerosis (ALS).
Methods: A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Four databases were searched from inception to April 2019: OVID Medline, Embase, PsycINFO, and CINAHL. Studies were included if (1) the sample represented individuals with ALS, (2) a generic PBM was utilized and reported on, and (3) information on the psychometric property of a generic PBM was provided.
Results: Ninety-one articles were screened, and 39 full-text articles were reviewed. Seven full-text articles were included in this review. The mean age of participants ranged from 58.1 to 63.8 years, and mean time since diagnosis ranged from 20.5 to 44.6 months. Two generic PBMs were found, the EQ-5D-3L (n = 6) and the Quality of Well-Being Self-Administered (QWB-SA) scale (n = 1). Convergent validity of the EQ-5D-3L was large against a global scale of self-perceived health (r = 0.60) and small to large against ALS specific HRQL measures (r = 0.19 to 0.75). For the QWB-SA scale, correlations were small against a generic measure (r = 0.21) and large against ALS specific measures (r = 0.55). The EQ-5D-3L discriminated across different disease severity; however, floor effects were reported.
Conclusion: This review highlights the need for more rigorously designed studies to assess the psychometric properties of generic PBMs in ALS and the development of an ALS specific PBM that adequately reflects the health concerns of individuals with ALS.
{"title":"Psychometric Properties of Preference-Based Measures for Economic Evaluation in Amyotrophic Lateral Sclerosis: A Systematic Review.","authors":"Nicole Peters, Vanina Dal Bello-Haas, Tara Packham, Ava Mehdipour, Ayse Kuspinar","doi":"10.1155/2021/6681554","DOIUrl":"https://doi.org/10.1155/2021/6681554","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this review was to synthesize the psychometric properties of generic preference-based measures (PBMs) of health-related quality of life (HRQL) in Amyotrophic Lateral Sclerosis (ALS).</p><p><strong>Methods: </strong>A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Four databases were searched from inception to April 2019: OVID Medline, Embase, PsycINFO, and CINAHL. Studies were included if (1) the sample represented individuals with ALS, (2) a generic PBM was utilized and reported on, and (3) information on the psychometric property of a generic PBM was provided.</p><p><strong>Results: </strong>Ninety-one articles were screened, and 39 full-text articles were reviewed. Seven full-text articles were included in this review. The mean age of participants ranged from 58.1 to 63.8 years, and mean time since diagnosis ranged from 20.5 to 44.6 months. Two generic PBMs were found, the EQ-5D-3L (<i>n</i> = 6) and the Quality of Well-Being Self-Administered (QWB-SA) scale (<i>n</i> = 1). Convergent validity of the EQ-5D-3L was large against a global scale of self-perceived health (<i>r</i> = 0.60) and small to large against ALS specific HRQL measures (<i>r</i> = 0.19 to 0.75). For the QWB-SA scale, correlations were small against a generic measure (<i>r</i> = 0.21) and large against ALS specific measures (<i>r</i> = 0.55). The EQ-5D-3L discriminated across different disease severity; however, floor effects were reported.</p><p><strong>Conclusion: </strong>This review highlights the need for more rigorously designed studies to assess the psychometric properties of generic PBMs in ALS and the development of an ALS specific PBM that adequately reflects the health concerns of individuals with ALS.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2021 ","pages":"6681554"},"PeriodicalIF":1.5,"publicationDate":"2021-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7861917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25360325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-22eCollection Date: 2021-01-01DOI: 10.1155/2021/8841281
Bademain Jean Fabrice Ido, Imen Kacem, Mahamadi Ouedraogo, Amina Nasri, Saloua Mrabet, Amina Gargouri, Mouna Ben Djebara, Bawindsongré Jean Kabore, Riadh Gouider
Background: Amyotrophic lateral sclerosis (ALS) is a fatal disease whose diagnosis and early management can improve survival. The most used diagnostic criteria are the revised El Escorial criteria (rEEC) and Awaji criteria (AC). The comparison of their sensitivities showed contradictory results. Our study aimed to compare the sensitivities of these two criteria in the diagnosis of definite ALS, at first visit, in a Tunisian hospital cohort.
Materials and methods: This was a retrospective study including 173 patients diagnosed with ALS at the Department of Neurology of the Razi Hospital between January 2003 and April 2018.After studying the clinical features of the disease in our study population,each patient was categorized according to the rEEC and AC based on data collected in his medical record during his first visit to our department. Then, we compared the sensitivities of these two criteria in the diagnosis of definite ALS.
Results: Our Tunisian cohort was characterized by a slower disease progression. The sensitivity of the AC (69.4%) was significantly higher than that of the rEEC (40.5%) (p < 0.001). When the clinical signs evolved for less than 6 months, the sensitivities were 61% for AC and 12% for rEEC (p < 0.001). After 24 months of disease progression, the sensitivities were 78.2% for AC and 69.1% for rEEC (p = 0.063). It was impossible to categorize seventeen patients by the two criteria.
Conclusion: Our study demonstrated that patients in AC are more sensitive than rEEC in the early diagnosis of ALS in our Tunisian cohort. However, this superiority is gradually reduced during the evolution of the disease.
背景:肌萎缩性侧索硬化症(ALS)是一种致命的疾病,其诊断和早期治疗可以提高生存率。最常用的诊断标准是经修订的El Escorial标准(rEEC)和Awaji标准(AC)。它们的灵敏度比较显示出相互矛盾的结果。我们的研究旨在比较这两个标准在诊断明确ALS的敏感性,在突尼斯医院队列首次访问。材料和方法:这是一项回顾性研究,包括2003年1月至2018年4月期间在Razi医院神经内科诊断为ALS的173例患者。在研究了我们研究人群中疾病的临床特征后,根据患者首次来我科就诊时的病历资料,将每位患者按照rEEC和AC进行分类。然后,我们比较了这两个标准在诊断明确ALS中的敏感性。结果:我们的突尼斯队列的特点是疾病进展较慢。AC的灵敏度(69.4%)显著高于rEEC (40.5%) (p p p = 0.063)。根据这两个标准对17例患者进行分类是不可能的。结论:我们的研究表明,在我们的突尼斯队列中,AC患者比rEEC患者对ALS的早期诊断更敏感。然而,这种优势在疾病的发展过程中逐渐减少。
{"title":"Sensitivity of Awaji Criteria and Revised El Escorial Criteria in the Diagnosis of Amyotrophic Lateral Sclerosis (ALS) at First Visit in a Tunisian Cohort.","authors":"Bademain Jean Fabrice Ido, Imen Kacem, Mahamadi Ouedraogo, Amina Nasri, Saloua Mrabet, Amina Gargouri, Mouna Ben Djebara, Bawindsongré Jean Kabore, Riadh Gouider","doi":"10.1155/2021/8841281","DOIUrl":"https://doi.org/10.1155/2021/8841281","url":null,"abstract":"<p><strong>Background: </strong>Amyotrophic lateral sclerosis (ALS) is a fatal disease whose diagnosis and early management can improve survival. The most used diagnostic criteria are the revised El Escorial criteria (rEEC) and Awaji criteria (AC). The comparison of their sensitivities showed contradictory results. Our study aimed to compare the sensitivities of these two criteria in the diagnosis of definite ALS, at first visit, in a Tunisian hospital cohort.</p><p><strong>Materials and methods: </strong>This was a retrospective study including 173 patients diagnosed with ALS at the Department of Neurology of the Razi Hospital between January 2003 and April 2018.After studying the clinical features of the disease in our study population,each patient was categorized according to the rEEC and AC based on data collected in his medical record during his first visit to our department. Then, we compared the sensitivities of these two criteria in the diagnosis of definite ALS.</p><p><strong>Results: </strong>Our Tunisian cohort was characterized by a slower disease progression. The sensitivity of the AC (69.4%) was significantly higher than that of the rEEC (40.5%) (<i>p</i> < 0.001). When the clinical signs evolved for less than 6 months, the sensitivities were 61% for AC and 12% for rEEC (<i>p</i> < 0.001). After 24 months of disease progression, the sensitivities were 78.2% for AC and 69.1% for rEEC (<i>p</i> = 0.063). It was impossible to categorize seventeen patients by the two criteria.</p><p><strong>Conclusion: </strong>Our study demonstrated that patients in AC are more sensitive than rEEC in the early diagnosis of ALS in our Tunisian cohort. However, this superiority is gradually reduced during the evolution of the disease.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2021 ","pages":"8841281"},"PeriodicalIF":1.5,"publicationDate":"2021-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25341755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-15eCollection Date: 2020-01-01DOI: 10.1155/2020/8871870
Marcos Serrano-Dueñas, Luis Masabanda, Maria-Rosario Luquin
Objective: This study has been designed with the aim of using optimal scaling to perform the allocation of scores and to be able to construct an indicator of the Parkinson's Disease Gravity Index. Scores were assigned to interrelated dimensions that share information about the patient's situation, to have an objective, holistic tool which integrates scores so that doctors can have a comprehensive idea of the patient's situation. Patients and Methods. 120 consecutive patients with Parkinson's diagnosis were chosen according to the United Kingdom Parkinson's Disease Society Brain Bank criteria. Subsequently, all the chosen dimensions were transformed into interval variables for which the formula proposed by Sturges was used. Once the dimensions were transformed into interval variables, optimal scaling was carried out. Subsequently, the following attributes were analyzed: quality and acceptability of the data; reliability: internal consistency, reliability index, Cronbach's alpha, and standard error of measurement; finally, validity: convergent validity and validity for known groups.
Results: There were no missing data. An appropriate Cronbach's alpha value of 0.71 was gathered, and all items were found to be pertinent to the scale. The item homogeneity index was 0.36. Precision evaluated with the standard error of measurement was 7.8. The Parkinson's Disease Gravity Index discriminant validity (validity for known groups), assessed among the different stages of Hoehn and Yahr scale by the Kruskal-Wallis test, showed major significance (X2 = 32.7, p ≤ 0.001).
Conclusions: The Parkinson's Disease Gravity Index has shown adequate metric properties.
{"title":"Parkinson's Disease Gravity Index: A Method by means of Optimal Scaling.","authors":"Marcos Serrano-Dueñas, Luis Masabanda, Maria-Rosario Luquin","doi":"10.1155/2020/8871870","DOIUrl":"10.1155/2020/8871870","url":null,"abstract":"<p><strong>Objective: </strong>This study has been designed with the aim of using optimal scaling to perform the allocation of scores and to be able to construct an indicator of the Parkinson's Disease Gravity Index. Scores were assigned to interrelated dimensions that share information about the patient's situation, to have an objective, holistic tool which integrates scores so that doctors can have a comprehensive idea of the patient's situation. <i>Patients and Methods.</i> 120 consecutive patients with Parkinson's diagnosis were chosen according to the United Kingdom Parkinson's Disease Society Brain Bank criteria. Subsequently, all the chosen dimensions were transformed into interval variables for which the formula proposed by Sturges was used. Once the dimensions were transformed into interval variables, optimal scaling was carried out. Subsequently, the following attributes were analyzed: quality and acceptability of the data; reliability: internal consistency, reliability index, Cronbach's alpha, and standard error of measurement; finally, validity: convergent validity and validity for known groups.</p><p><strong>Results: </strong>There were no missing data. An appropriate Cronbach's alpha value of 0.71 was gathered, and all items were found to be pertinent to the scale. The item homogeneity index was 0.36. Precision evaluated with the standard error of measurement was 7.8. The Parkinson's Disease Gravity Index discriminant validity (validity for known groups), assessed among the different stages of Hoehn and Yahr scale by the Kruskal-Wallis test, showed major significance (<i>X</i> <sup>2</sup> = 32.7, <i>p</i> ≤ 0.001).</p><p><strong>Conclusions: </strong>The Parkinson's Disease Gravity Index has shown adequate metric properties.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2020 ","pages":"8871870"},"PeriodicalIF":1.7,"publicationDate":"2020-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38767732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-22eCollection Date: 2020-01-01DOI: 10.1155/2020/8874424
Mohammad Mahdi Shahpouri, Majid Barekatain, Mahgol Tavakoli, Omid Mirmosayyeb, Ali Safaei, Vahid Shaygannejad
Background: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that affects cognitive performance and leads to depression and decreased quality of life (QOL). The current study aims to assess the effects of cognitive rehabilitation versus donepezil therapy on memory, attention, depression, and QOL in MS patients compared to placebo and control groups.
Methods: Eighty MS patients were randomly selected from parallel randomized trials and divided into four groups: A: cognitive rehabilitation (10 sessions of 120 minutes), B: control (no intervention), C: donepezil (10 mg daily), and D: placebo. Patients received the intervention for three months. They were assessed for cognitive status, depression, and QOL prior to the intervention and immediately after that using abbreviated mental test (AMT), prospective and retrospective memory questionnaire (PRMQ), everyday memory questionnaire (EMQ), digit span, MSQOL-54, and second edition Beck depression inventory (BDI). We compared scores between groups after the intervention, as well as the progression of scores in every single group.
Result: s. The cognitive rehabilitation group showed improvement in EMQ, RPMQ, digit span, physical and mental health subscales of MSQOL54, and depression (P < 0.05). We observed the same effect for donepezil except for the digit span test (P = 0.15). Intergroup comparison of scores showed the superiority of cognitive rehabilitation over donepezil in digit span, depression, and mental health scores.
Conclusion: Both donepezil and cognitive rehabilitation effectively improve memory performance, attention, depression, and QOL in MS patients. Cognitive rehabilitation is superior altogether. This study is registered with the Iranian registry of clinical trials http://clinicaltrials.gov/ct2/show/IRCT2016042227522N1.
{"title":"Comparison of Cognitive Rehabilitation versus Donepezil Therapy on Memory Performance, Attention, Quality of Life, and Depression among Multiple Sclerosis Patients.","authors":"Mohammad Mahdi Shahpouri, Majid Barekatain, Mahgol Tavakoli, Omid Mirmosayyeb, Ali Safaei, Vahid Shaygannejad","doi":"10.1155/2020/8874424","DOIUrl":"10.1155/2020/8874424","url":null,"abstract":"<p><strong>Background: </strong>Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that affects cognitive performance and leads to depression and decreased quality of life (QOL). The current study aims to assess the effects of cognitive rehabilitation versus donepezil therapy on memory, attention, depression, and QOL in MS patients compared to placebo and control groups.</p><p><strong>Methods: </strong>Eighty MS patients were randomly selected from parallel randomized trials and divided into four groups: A: cognitive rehabilitation (10 sessions of 120 minutes), B: control (no intervention), C: donepezil (10 mg daily), and D: placebo. Patients received the intervention for three months. They were assessed for cognitive status, depression, and QOL prior to the intervention and immediately after that using abbreviated mental test (AMT), prospective and retrospective memory questionnaire (PRMQ), everyday memory questionnaire (EMQ), digit span, MSQOL-54, and second edition Beck depression inventory (BDI). We compared scores between groups after the intervention, as well as the progression of scores in every single group.</p><p><strong>Result: </strong>s. The cognitive rehabilitation group showed improvement in EMQ, RPMQ, digit span, physical and mental health subscales of MSQOL54, and depression (<i>P</i> < 0.05). We observed the same effect for donepezil except for the digit span test (<i>P</i> = 0.15). Intergroup comparison of scores showed the superiority of cognitive rehabilitation over donepezil in digit span, depression, and mental health scores.</p><p><strong>Conclusion: </strong>Both donepezil and cognitive rehabilitation effectively improve memory performance, attention, depression, and QOL in MS patients. Cognitive rehabilitation is superior altogether. This study is registered with the Iranian registry of clinical trials http://clinicaltrials.gov/ct2/show/IRCT2016042227522N1.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2020 ","pages":"8874424"},"PeriodicalIF":1.5,"publicationDate":"2020-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38705804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-17eCollection Date: 2020-01-01DOI: 10.1155/2020/5090193
Mohamed E Khallaf
Objectives: Impairment of static and dynamic posture control is common after stroke. It is found to be a predictor and an essential component for balance, walking ability, and activities of daily living (ADL) outcomes. Studies investigating effect of physical therapy techniques with an aim to improve trunk function after stroke are limited. This study aimed at studying the effect of task-specific training on trunk control and balance in patients with subacute stroke.
Methods: In this randomized controlled trail, thirty-four patients were alienated into two equal groups. The study group (n = 17) received task-specific training, and the control group (n = 17) received conventional physical therapy based on the neurodevelopmental technique. Task-specific training was applied through two phases with criteria of progression based on Chedoke-McMaster Stroke Assessment postural control stages. The interventions were applied in a dosage of 60 min per session, three times a week for ten weeks. Static and dynamic balance were measured by the trunk impairment scale (TIS), postural assessment scale (PAS), and functional reach test (FRT). Laser-guided digital goniometer was used to measure the trunk ranges of motions (ROM) as a secondary outcome.
Results: Significant differences between the baseline and the follow-up measures including TIS, PAS, FRT, and trunk (ROM) were found in both groups (P ≤ 0.05). In-between group comparison also showed significant differences between the results of both groups indicating more improvements among patients representing the study group.
Conclusion: Task-specific training may be effective in improving the static and dynamic postural control and trunk ranges of motion among subacute stroke patients.
{"title":"Effect of Task-Specific Training on Trunk Control and Balance in Patients with Subacute Stroke.","authors":"Mohamed E Khallaf","doi":"10.1155/2020/5090193","DOIUrl":"https://doi.org/10.1155/2020/5090193","url":null,"abstract":"<p><strong>Objectives: </strong>Impairment of static and dynamic posture control is common after stroke. It is found to be a predictor and an essential component for balance, walking ability, and activities of daily living (ADL) outcomes. Studies investigating effect of physical therapy techniques with an aim to improve trunk function after stroke are limited. This study aimed at studying the effect of task-specific training on trunk control and balance in patients with subacute stroke.</p><p><strong>Methods: </strong>In this randomized controlled trail, thirty-four patients were alienated into two equal groups. The study group (<i>n</i> = 17) received task-specific training, and the control group (<i>n</i> = 17) received conventional physical therapy based on the neurodevelopmental technique. Task-specific training was applied through two phases with criteria of progression based on Chedoke-McMaster Stroke Assessment postural control stages. The interventions were applied in a dosage of 60 min per session, three times a week for ten weeks. Static and dynamic balance were measured by the trunk impairment scale (TIS), postural assessment scale (PAS), and functional reach test (FRT). Laser-guided digital goniometer was used to measure the trunk ranges of motions (ROM) as a secondary outcome.</p><p><strong>Results: </strong>Significant differences between the baseline and the follow-up measures including TIS, PAS, FRT, and trunk (ROM) were found in both groups (<i>P</i> ≤ 0.05). In-between group comparison also showed significant differences between the results of both groups indicating more improvements among patients representing the study group.</p><p><strong>Conclusion: </strong>Task-specific training may be effective in improving the static and dynamic postural control and trunk ranges of motion among subacute stroke patients.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2020 ","pages":"5090193"},"PeriodicalIF":1.5,"publicationDate":"2020-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/5090193","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38689339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-04eCollection Date: 2020-01-01DOI: 10.1155/2020/7397480
Ademola S Ojo, Simon A Balogun, Ahmed O Idowu
The emergence and spread of the highly contagious novel coronavirus disease (COVID-19) have triggered the greatest public health challenge of the last century. Aside from being a primary respiratory disease, acute ischemic stroke has emerged as a complication of the disease. While current evidence shows COVID-19 could cause ischemic stroke especially in severe disease, there are similarities in the risk factors for severe COVID-19 as well as ischemic stroke, underscoring the complex relationship between these two conditions. The pandemic has created challenges for acute stroke care. Rapid assessment and time-sensitive interventions required for optimum outcomes in acute stroke care have been complicated by COVID-19 due to the need for disease transmission preventive measures. The purpose of this article is to explore the putative mechanisms of ischemic stroke in COVID-19 and the clinical characteristics of COVID-19 patients who develop ischemic stroke. In addition, we discuss the challenges of managing acute ischemic stroke in the setting of COVID-19 and review current management guidelines. We also highlighted potential areas for future research.
{"title":"Acute Ischemic Stroke in COVID-19: Putative Mechanisms, Clinical Characteristics, and Management.","authors":"Ademola S Ojo, Simon A Balogun, Ahmed O Idowu","doi":"10.1155/2020/7397480","DOIUrl":"10.1155/2020/7397480","url":null,"abstract":"<p><p>The emergence and spread of the highly contagious novel coronavirus disease (COVID-19) have triggered the greatest public health challenge of the last century. Aside from being a primary respiratory disease, acute ischemic stroke has emerged as a complication of the disease. While current evidence shows COVID-19 could cause ischemic stroke especially in severe disease, there are similarities in the risk factors for severe COVID-19 as well as ischemic stroke, underscoring the complex relationship between these two conditions. The pandemic has created challenges for acute stroke care. Rapid assessment and time-sensitive interventions required for optimum outcomes in acute stroke care have been complicated by COVID-19 due to the need for disease transmission preventive measures. The purpose of this article is to explore the putative mechanisms of ischemic stroke in COVID-19 and the clinical characteristics of COVID-19 patients who develop ischemic stroke. In addition, we discuss the challenges of managing acute ischemic stroke in the setting of COVID-19 and review current management guidelines. We also highlighted potential areas for future research.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2020 ","pages":"7397480"},"PeriodicalIF":1.7,"publicationDate":"2020-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38736731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-29eCollection Date: 2020-01-01DOI: 10.1155/2020/8834299
Fikru Tsehayneh, Abenet Tafesse
Background: There is limited information and research carried out regarding the prevalence of poststroke depression (PSD) in the study area. Psychiatric disorders complicate a significant proportion of patients suffering from stroke. This of course have a great negative impact on our knowledge about poststroke depression in Ethiopia, and poststroke depression complicates a significant number of stroke patients and their rehabilitation.
Methods: A cross-sectional study on all patients aged above 18 years and diagnosed with stroke in the past two years who attended the neurology follow-up clinics of Tikur Anbessa Specialized Hospital (TASH) and Zewditu Memorial Hospital (ZMH) was done by using a structured questionnaire containing Patient Health Questionnaire-9 (PHQ-9) depression screening tool.
Result: Of 84 patients who were eligible for the study, 32.2% of patients have depressive symptoms. Women (OR 0.001, 95% CI 0.12-0.87) and aphasic patients (OR 0.034, 95% CI 0.19-1.27) were more likely to have depressive symptoms.
Conclusion: Depressive symptoms after stroke are common in Ethiopian patients. Our study demonstrates female and aphasic patients are more likely to screen positive for PSD. Hence, screening all poststroke patients with different screening tools is practical, and further studies are needed to assess the validity of these screening tools and also to assess PSD as a predictor of stroke outcome.
背景:关于研究地区脑卒中后抑郁(PSD)患病率的信息和研究有限。很大一部分中风患者因精神疾病而复杂化。这当然对我们对埃塞俄比亚中风后抑郁症的认识产生了很大的负面影响,而且中风后抑郁症使大量中风患者及其康复复杂化。方法:采用包含患者健康问卷-9 (PHQ-9)抑郁筛查工具的结构化问卷,对Tikur Anbessa专科医院(TASH)和Zewditu纪念医院(ZMH)神经病学随访门诊近2年所有18岁以上卒中患者进行横断面研究。结果:84例符合研究条件的患者中,32.2%的患者有抑郁症状。女性(OR 0.001, 95% CI 0.12-0.87)和失语症患者(OR 0.034, 95% CI 0.19-1.27)更容易出现抑郁症状。结论:卒中后抑郁症状在埃塞俄比亚患者中很常见。我们的研究表明,女性和失语患者更有可能筛查出PSD阳性。因此,使用不同的筛查工具对所有脑卒中后患者进行筛查是可行的,需要进一步的研究来评估这些筛查工具的有效性,并评估PSD作为脑卒中预后的预测因子。
{"title":"High Prevalence of Poststroke Depression in Ischemic Stroke Patients in Ethiopia.","authors":"Fikru Tsehayneh, Abenet Tafesse","doi":"10.1155/2020/8834299","DOIUrl":"https://doi.org/10.1155/2020/8834299","url":null,"abstract":"<p><strong>Background: </strong>There is limited information and research carried out regarding the prevalence of poststroke depression (PSD) in the study area. Psychiatric disorders complicate a significant proportion of patients suffering from stroke. This of course have a great negative impact on our knowledge about poststroke depression in Ethiopia, and poststroke depression complicates a significant number of stroke patients and their rehabilitation.</p><p><strong>Methods: </strong>A cross-sectional study on all patients aged above 18 years and diagnosed with stroke in the past two years who attended the neurology follow-up clinics of Tikur Anbessa Specialized Hospital (TASH) and Zewditu Memorial Hospital (ZMH) was done by using a structured questionnaire containing Patient Health Questionnaire-9 (PHQ-9) depression screening tool.</p><p><strong>Result: </strong>Of 84 patients who were eligible for the study, 32.2% of patients have depressive symptoms. Women (OR 0.001, 95% CI 0.12-0.87) and aphasic patients (OR 0.034, 95% CI 0.19-1.27) were more likely to have depressive symptoms.</p><p><strong>Conclusion: </strong>Depressive symptoms after stroke are common in Ethiopian patients. Our study demonstrates female and aphasic patients are more likely to screen positive for PSD. Hence, screening all poststroke patients with different screening tools is practical, and further studies are needed to assess the validity of these screening tools and also to assess PSD as a predictor of stroke outcome.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2020 ","pages":"8834299"},"PeriodicalIF":1.5,"publicationDate":"2020-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/8834299","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38591219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-28eCollection Date: 2020-01-01DOI: 10.1155/2020/8886828
Misganaw Tilahun, Netsanet Habte, Kenean Mekonnen, Mengesha Srahbzu, Daniel Ayelegne
Introduction: Nonadherence to antiepileptic medication is the extent of a patient's passive failure to follow the prescribed therapeutic regimen. The prevalence and impact of nonadherence to antiepileptic medication are high globally. The main purpose of this study was to assess nonadherence to antiepileptic medications and its associated factors among epileptic patients at the University of Gondar Referral Hospital, Gondar, Ethiopia, 2019.
Methods: An institutional-based cross-sectional study was conducted among 365 epileptic patients at the University of Gondar Referral Hospital, who were selected by a systematic random sampling technique. Data were collected by face to face interviews using a structured pretested questionnaire. Data were entered into EPI Info version 7 and then exported to SPSS version 22 for analysis. The data were described by descriptive statistics. Binary logistic regression analysis was used as a model, and variables with a p value of less than 0.05 were considered as statistically significant with nonadherence to antiepileptic medications.
Results: A total of 356 epileptic patients participated in the study yielding a response rate of 97.5%. The overall prevalence of nonadherence to antiepileptic medications among epileptic patients attending at the University of Gondar Referral Hospital was 38.5% (95% CI: 33.1-43.8). Divorced and/or widowed marital status (AOR: 3.38 (95% CI: 1.54, 7.44)), treatment duration of 3-5 years (AOR = 3.58 (95% CI: 1.38, 9.29)), treatment duration of 5 and above years (AOR: 3.49 (95% CI: 1.53, 7.95)), comorbidity (AOR: 2.42 (95% CI: 1.08, 5.43)), side effects of antiepileptic medications (AOR: 3.36 (95% CI: 1.67, 6.74)), absence of health information (AOR: 1.98 (95% CI: 1.11, 3.52)), epilepsy-related stigma (AOR: 2.81 (95% CI: 1.57, 5.02)), and negative attitude towards antiepileptic medications (AOR: 2.46 (95% CI: 1.36, 4.45)) were significantly associated with nonadherence to antiepileptic medications.
Conclusions: Prevalence of nonadherence to antiepileptic medications among epileptic patients at the University of Gondar Referral Hospital was found to be high. Hence, giving health information about epilepsy and its management will help to reduce antiepileptic medications' nonadherence.
{"title":"Nonadherence to Antiepileptic Medications and Its Determinants among Epileptic Patients at the University of Gondar Referral Hospital, Gondar, Ethiopia, 2019: An Institutional-Based Cross-Sectional Study.","authors":"Misganaw Tilahun, Netsanet Habte, Kenean Mekonnen, Mengesha Srahbzu, Daniel Ayelegne","doi":"10.1155/2020/8886828","DOIUrl":"https://doi.org/10.1155/2020/8886828","url":null,"abstract":"<p><strong>Introduction: </strong>Nonadherence to antiepileptic medication is the extent of a patient's passive failure to follow the prescribed therapeutic regimen. The prevalence and impact of nonadherence to antiepileptic medication are high globally. The main purpose of this study was to assess nonadherence to antiepileptic medications and its associated factors among epileptic patients at the University of Gondar Referral Hospital, Gondar, Ethiopia, 2019.</p><p><strong>Methods: </strong>An institutional-based cross-sectional study was conducted among 365 epileptic patients at the University of Gondar Referral Hospital, who were selected by a systematic random sampling technique. Data were collected by face to face interviews using a structured pretested questionnaire. Data were entered into EPI Info version 7 and then exported to SPSS version 22 for analysis. The data were described by descriptive statistics. Binary logistic regression analysis was used as a model, and variables with a <i>p</i> value of less than 0.05 were considered as statistically significant with nonadherence to antiepileptic medications.</p><p><strong>Results: </strong>A total of 356 epileptic patients participated in the study yielding a response rate of 97.5%. The overall prevalence of nonadherence to antiepileptic medications among epileptic patients attending at the University of Gondar Referral Hospital was 38.5% (95% CI: 33.1-43.8). Divorced and/or widowed marital status (AOR: 3.38 (95% CI: 1.54, 7.44)), treatment duration of 3-5 years (AOR = 3.58 (95% CI: 1.38, 9.29)), treatment duration of 5 and above years (AOR: 3.49 (95% CI: 1.53, 7.95)), comorbidity (AOR: 2.42 (95% CI: 1.08, 5.43)), side effects of antiepileptic medications (AOR: 3.36 (95% CI: 1.67, 6.74)), absence of health information (AOR: 1.98 (95% CI: 1.11, 3.52)), epilepsy-related stigma (AOR: 2.81 (95% CI: 1.57, 5.02)), and negative attitude towards antiepileptic medications (AOR: 2.46 (95% CI: 1.36, 4.45)) were significantly associated with nonadherence to antiepileptic medications.</p><p><strong>Conclusions: </strong>Prevalence of nonadherence to antiepileptic medications among epileptic patients at the University of Gondar Referral Hospital was found to be high. Hence, giving health information about epilepsy and its management will help to reduce antiepileptic medications' nonadherence.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2020 ","pages":"8886828"},"PeriodicalIF":1.5,"publicationDate":"2020-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/8886828","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38608326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-23eCollection Date: 2020-01-01DOI: 10.1155/2020/6718915
Devender Bhalla, Elham Lotfalinezhad, Fatemeh Amini, Ahmad Delbari, Reza Fadaye-Vatan, Vida Saii, Kurosh Gharagozli
<p><strong>Introduction: </strong>The primary objective of our study was to determine the nature of medication beliefs and their association with adherence to antiseizure medications (ASMs) among elderly epilepsy patients. Our secondary objective was to enhance the psychometric properties and factor structure parameters of the Beliefs about Medications Questionnaire (BMQ) adapted to epilepsy and affected aged subjects.</p><p><strong>Methods: </strong>A population-based survey was performed in which older adults (≥60 years of age) were invited for a free face-to-face consultation with the specialists as well as for the collection of necessary data. The eligible subjects were those who are affected with epilepsy and having epileptic seizures of any type. In addition, the participants were required to be of any sex, currently under treatment with ASMs, resident of Tehran, and able and interested to participate independently. All were carefully examined with a reasonably detailed case-history examination. Two Persian questionnaires used were Medication Adherence Rating Scale (MARS) and BMQ. Those with a MARS score of ≥6 were considered as adherent to ASMs. All data were described in descriptive terms. We did a group comparison of means and proportions for all possible independent variables between adherents and nonadherents. Then, we did a hierarchical multiple linear regression. For this, independent variables were categorized into three different blocks: (a) sociodemographic block (Block-1), (b) treatment side-effect block (Block-2), and (c) BMQ block that included ten items of the BMQ scale (Block-3). We also did a forward step-wise linear regression by beginning with an empty model. We also estimated the psychometric properties and factor structure parameters of BMQ and its two subdomains.</p><p><strong>Results: </strong>Of all (<i>N</i> = 123, mean age: 63.3 years, 74.0% males), 78.0% were adherent (mean score: 7.0, 95% CI 6.2-7.8) to ASMs. The MARS scores were not different between males and females. The mean BMQ score was 23.4 (95% CI 19.8-27.0) with the mean need score of 20.0 (95% CI 18.0-22.0) and mean concern score of 16.5 (95% CI 14.3-18.7). A positive need-concern differential was 20.4%. Upon hierarchical regression, the adjusted <i>R</i> <sup>2</sup> for Block-1 was 33.8%, and it was 53.8% for Block-2 and 92.2% for Block-3. Upon forward step-wise linear regression, we found that "ASMs disrupt my life" (<i>ß</i> -1.9, ES = -1.1, <i>p</i>=0.008) as the only belief associated with adherence. The alpha coefficient of BMQ was 0.81.</p><p><strong>Conclusions: </strong>Ours is one of the very few studies that evaluated medication beliefs and their association with adherence to ASMs among elderly epilepsy patients in a non-western context. In our context, medication beliefs are likely to have an independent role in effecting adherence to ASMs, particularly the concern that "ASMs disrupt life." Treating physicians should cultivate good conscienc
前言:本研究的主要目的是确定老年癫痫患者用药信念的性质及其与抗癫痫药物依从性的关系。我们的次要目的是提高《药物治疗信念问卷》(BMQ)的心理测量特性和因素结构参数,以适应癫痫和老年患者。方法:以人群为基础进行调查,邀请老年人(≥60岁)与专家进行免费面对面咨询,并收集必要的数据。符合条件的受试者是那些受癫痫影响和有任何类型癫痫发作的人。此外,参与者被要求是任何性别,目前正在接受asm治疗,德黑兰居民,能够并有兴趣独立参与。所有病例均经过相当详细的病例史检查。使用的两份波斯语问卷分别是药物依从性评定量表(MARS)和BMQ。MARS评分≥6分的患者被认为符合asm。所有数据均以描述性术语描述。我们对信徒和非信徒之间所有可能的自变量的均值和比例进行了分组比较。然后,我们做了一个层次多元线性回归。为此,将自变量分为三个不同的块:(a)社会人口统计学块(block -1), (b)治疗副作用块(block -2),以及(c) BMQ块,包括BMQ量表的十个项目(block -3)。我们也做了一个前向逐步线性回归,从一个空模型开始。我们还估计了BMQ及其两个子域的心理测量特性和因子结构参数。结果:123例患者(N = 123,平均年龄:63.3岁,男性74.0%),78.0%的患者(平均评分:7.0,95% CI: 6.2-7.8)坚持使用asm。MARS得分在男性和女性之间没有差异。平均BMQ评分为23.4 (95% CI 19.8-27.0),平均需求评分为20.0 (95% CI 18.0-22.0),平均关注评分为16.5 (95% CI 14.3-18.7)。阳性需求-关注差异为20.4%。经层次回归,Block-1的调整后r2为33.8%,Block-2和Block-3的调整后r2分别为53.8%和92.2%。通过前向逐步线性回归,我们发现“asm扰乱了我的生活”(ß -1.9, ES = -1.1, p=0.008)是唯一与依从性相关的信念。BMQ α系数为0.81。结论:我们的研究是少数评估非西方背景下老年癫痫患者的用药信念及其与抗痉挛药物依从性的关系的研究之一。在我们的背景下,药物信念可能在影响对asm的依从性方面具有独立的作用,特别是对“asm扰乱生活”的担忧。治疗医生应该培养对asm的良知,并尽早评估患者的用药信念,以确定哪些人可能有不坚持的风险。
{"title":"Medication Beliefs and Adherence to Antiseizure Medications.","authors":"Devender Bhalla, Elham Lotfalinezhad, Fatemeh Amini, Ahmad Delbari, Reza Fadaye-Vatan, Vida Saii, Kurosh Gharagozli","doi":"10.1155/2020/6718915","DOIUrl":"https://doi.org/10.1155/2020/6718915","url":null,"abstract":"<p><strong>Introduction: </strong>The primary objective of our study was to determine the nature of medication beliefs and their association with adherence to antiseizure medications (ASMs) among elderly epilepsy patients. Our secondary objective was to enhance the psychometric properties and factor structure parameters of the Beliefs about Medications Questionnaire (BMQ) adapted to epilepsy and affected aged subjects.</p><p><strong>Methods: </strong>A population-based survey was performed in which older adults (≥60 years of age) were invited for a free face-to-face consultation with the specialists as well as for the collection of necessary data. The eligible subjects were those who are affected with epilepsy and having epileptic seizures of any type. In addition, the participants were required to be of any sex, currently under treatment with ASMs, resident of Tehran, and able and interested to participate independently. All were carefully examined with a reasonably detailed case-history examination. Two Persian questionnaires used were Medication Adherence Rating Scale (MARS) and BMQ. Those with a MARS score of ≥6 were considered as adherent to ASMs. All data were described in descriptive terms. We did a group comparison of means and proportions for all possible independent variables between adherents and nonadherents. Then, we did a hierarchical multiple linear regression. For this, independent variables were categorized into three different blocks: (a) sociodemographic block (Block-1), (b) treatment side-effect block (Block-2), and (c) BMQ block that included ten items of the BMQ scale (Block-3). We also did a forward step-wise linear regression by beginning with an empty model. We also estimated the psychometric properties and factor structure parameters of BMQ and its two subdomains.</p><p><strong>Results: </strong>Of all (<i>N</i> = 123, mean age: 63.3 years, 74.0% males), 78.0% were adherent (mean score: 7.0, 95% CI 6.2-7.8) to ASMs. The MARS scores were not different between males and females. The mean BMQ score was 23.4 (95% CI 19.8-27.0) with the mean need score of 20.0 (95% CI 18.0-22.0) and mean concern score of 16.5 (95% CI 14.3-18.7). A positive need-concern differential was 20.4%. Upon hierarchical regression, the adjusted <i>R</i> <sup>2</sup> for Block-1 was 33.8%, and it was 53.8% for Block-2 and 92.2% for Block-3. Upon forward step-wise linear regression, we found that \"ASMs disrupt my life\" (<i>ß</i> -1.9, ES = -1.1, <i>p</i>=0.008) as the only belief associated with adherence. The alpha coefficient of BMQ was 0.81.</p><p><strong>Conclusions: </strong>Ours is one of the very few studies that evaluated medication beliefs and their association with adherence to ASMs among elderly epilepsy patients in a non-western context. In our context, medication beliefs are likely to have an independent role in effecting adherence to ASMs, particularly the concern that \"ASMs disrupt life.\" Treating physicians should cultivate good conscienc","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2020 ","pages":"6718915"},"PeriodicalIF":1.5,"publicationDate":"2020-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/6718915","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38683848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}